WO2024114789A1 - Composition pharmaceutique comprenant du trifarotène et son utilisation - Google Patents

Composition pharmaceutique comprenant du trifarotène et son utilisation Download PDF

Info

Publication number
WO2024114789A1
WO2024114789A1 PCT/CN2023/135836 CN2023135836W WO2024114789A1 WO 2024114789 A1 WO2024114789 A1 WO 2024114789A1 CN 2023135836 W CN2023135836 W CN 2023135836W WO 2024114789 A1 WO2024114789 A1 WO 2024114789A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
trefarotene
skin
emulsifier
content
Prior art date
Application number
PCT/CN2023/135836
Other languages
English (en)
Chinese (zh)
Inventor
刘飞
姜伟化
康乐
王旋
王露露
郑敏
张翠霞
Original Assignee
南京迈诺威医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京迈诺威医药科技有限公司 filed Critical 南京迈诺威医药科技有限公司
Publication of WO2024114789A1 publication Critical patent/WO2024114789A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • Patent application number 202211543234.1 filed with the State Intellectual Property Office of China on December 2, 2022, and the invention name is “A pharmaceutical composition containing trefarotene and its application”.
  • the entire text of the prior application is incorporated into this application by reference.
  • the invention belongs to the field of pharmaceutical compositions, and in particular relates to a topical pharmaceutical composition containing trefarotene and an application thereof.
  • Trifarotene (Formula I) is a selective ⁇ -retinoic acid receptor (RAR) agonist and keratolytic agent.
  • RAR retinoic acid receptor
  • FDA U.S. Food and Drug Administration
  • Galderma's Trifarotene Cream (trade name Aklief) for topical treatment of acne. This is the first retinoid molecule approved by the U.S. FDA for the treatment of facial and trunk acne, and belongs to the fourth generation of topical retinoid drugs.
  • Patent document CN 104507470 A discloses a topical composition of an oil-in-water emulsion type containing a retinoid, wherein the composition comprises a fat phase and an aqueous phase, wherein the fat phase comprises trefarotene, phenoxyethanol, one or more cosolvents and mineral oil, and the aqueous phase comprises at least one sucrose ester surfactant, at least one polyol and purified water.
  • the emulsion has skin irritation, such as erythema, desquamation, skin burning sensation, dryness, itching and other skin adverse reactions.
  • Patent document CN 114848593 A discloses a foam composition comprising a retinoic acid drug, a surfactant and an aqueous solvent.
  • the foam composition is mainly used for cosmetic purposes, has a short duration of action, and is difficult to exert the therapeutic effect of the drug.
  • the purpose of the present invention is to overcome the above-mentioned defects and provide a pharmaceutical composition containing trefarotene which has good stability, low irritation and is comfortable to use.
  • the present invention provides the following technical solutions:
  • the first aspect of the present invention provides a pharmaceutical composition containing trefarotene, which comprises trefarotene, oil, emulsifier and water;
  • the oil is selected from at least one of caprylic capric triglyceride, caprylic triglyceride, isopropyl myristate, and mineral oil;
  • the emulsifier is selected from at least one of sorbitan oleate (Span 80) and oleic acid macrogol glyceride (Labrafil M 1944CS).
  • the oil is selected from at least one of caprylic capric triglyceride and caprylic triglyceride.
  • the emulsifier is sorbitan oleate (Span 80).
  • the content of the active ingredient trefarotene can be 0.001-0.1wt% of the pharmaceutical composition, preferably 0.001-0.01wt%, for example 0.001wt%, 0.002wt%, 0.0025wt%, 0.003wt%, 0.004wt%, 0.005wt%, 0.006wt%, 0.008wt%, etc.
  • the content of the oil may be 0.1-20 wt %, preferably 1-10 wt %, such as 1 wt %, 3 wt %, 4 wt %, 5 wt % or 8 wt % of the pharmaceutical composition.
  • the content of the emulsifier can be 0.01-10wt% of the pharmaceutical composition, preferably 0.1-7wt%, for example 0.2wt%, 0.8wt%, 1wt%, 1.4wt%, 2wt%, 3.4wt% or 5wt%.
  • the pharmaceutical composition comprises the following components: 0.001-0.1 wt% of trefarotene; 2-8 wt% of oil; 0.2-6 wt% of emulsifier, and water added to 100 wt%.
  • the pharmaceutical composition of the present invention may optionally include at least one of a solubilizer, an emulsifying thickener, and a pH adjuster.
  • the solubilizing agent is selected from one or both of phenoxyethanol and ethanol.
  • the content of the solubilizer may be in the range of 0.5 to 10 wt % of the pharmaceutical composition, preferably 0.6 to 8 wt %, such as 0.8 wt %, 4 wt % or 6 wt %.
  • the emulsifying thickener is selected from at least one of polyacrylamide emulsifying thickeners (such as SEPIGEL 305, SIMULGEL EG, SIMULGEL FL, SIMULGEL 600 from SEPPIC) and acrylate emulsifying thickeners (such as Pemulen TR-1 or 2 from Lubrizol); more preferably, the emulsifying thickener is Pemulen TR-1.
  • polyacrylamide emulsifying thickeners such as SEPIGEL 305, SIMULGEL EG, SIMULGEL FL, SIMULGEL 600 from SEPPIC
  • acrylate emulsifying thickeners such as Pemulen TR-1 or 2 from Lubrizol
  • the content of the emulsifying thickener can be 0.1-5wt% of the pharmaceutical composition, preferably 0.2-2wt%, for example 0.4wt%, 0.5wt%, 0.8wt%, 1wt%.
  • the pH regulator is selected from one or both of triethanolamine and sodium hydroxide; more preferably, the pH regulator is triethanolamine.
  • the actual amount of the pH regulator is very small, and only an appropriate amount is needed to adjust the pH of the pharmaceutical composition to 4.5-7.5, preferably 5.0-7.0.
  • the pharmaceutical composition of the present invention comprises the following components:
  • trefarotene 0.001-0.1wt% of trefarotene; 2-8wt% of oil; 0.2-6wt% of emulsifier; 1-8wt% of solubilizer; 0.2-1.0wt% of emulsifying thickener; an appropriate amount of pH regulator to adjust the pH of the pharmaceutical composition to 4.5-7.5; and water to 100wt%.
  • the pharmaceutical composition comprises the following components:
  • trefarotene 0.001-0.1wt% of trefarotene; 2-5wt% of oil; 0.4-3wt% of emulsifier; 1-6wt% of solubilizer; 0.3-0.8wt% of emulsifying thickener; an appropriate amount of pH regulator to adjust the pH of the pharmaceutical composition to 5.0-7.0; and water to 100wt%.
  • the pharmaceutical composition of the present invention may optionally include other pharmaceutically acceptable excipients, such as at least one of a humectant, an antioxidant, a lubricant, a preservative, and the like.
  • the humectant can be selected from commonly used humectants known in the art, for example, at least one selected from glycerol, propylene glycol, sodium hyaluronate, and allantoin.
  • the humectant can be optionally added in a conventional amount.
  • the content of the humectant can be 0 to 30 wt %, such as 0 to 15 wt %, such as 0.05 wt %, 0.1 wt %, 0.5 wt %, 1 wt %, 5 wt %, 10 wt %, 12 wt % of the pharmaceutical composition.
  • the antioxidant can be selected from commonly used antioxidants known in the art, for example, selected from at least one of sodium pyrosulfite, sodium bisulfite, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), tocopherol, tocopherol acetate, tocopherol nicotinate, ascorbic acid, ascorbyl tetraisopalmitate, sodium ascorbyl phosphate, and magnesium ascorbyl phosphate.
  • BHT butylated hydroxytoluene
  • BHA butylated hydroxyanisole
  • the antioxidant can be optionally added in a conventional amount.
  • the content of the antioxidant can be 0 to 2wt% of the pharmaceutical composition, for example 0 to 1wt%, for example 0.05wt%, 0.1wt%, 0.2wt%, 0.5wt%, and 0.8wt%.
  • the lubricant can be selected from commonly used lubricants known in the art, for example, at least one selected from cyclomethicone, cyclopolydimethylsiloxane, polymethylsilsesquioxane, and polydimethylsiloxane.
  • the lubricant can be optionally added in a conventional amount.
  • the content of the lubricant can be 0 to 2 wt% of the pharmaceutical composition, such as 0 to 1 wt%, such as 0.05 wt%, 0.1 wt%, 0.3 wt%, 0.5 wt%, 0.8 wt%.
  • the preservative can be selected from commonly used preservatives known in the art, for example, selected from at least one of phenoxyethanol, benzyl alcohol, butylene glycol, hexylene glycol, pentylene glycol, p-hydroxyacetophenone, ethylhexylglycerin, and methylparaben.
  • the preservative can be optionally added in a conventional amount.
  • the content of the preservative can be 0 to 5wt% of the pharmaceutical composition, such as 0 to 3wt%, such as 0.05wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.5wt%, 0.8wt%, 1wt%.
  • the pharmaceutical composition of the present invention comprises the following components:
  • the pharmaceutical composition of the present invention comprises the following components:
  • the pharmaceutical composition of the present invention includes the following components: 0.005 wt% of trefarotene, 3 wt% of caprylic capric triglyceride, 0.8 wt% of sorbitan oleate, a pH adjuster to adjust the pH of the pharmaceutical composition to 5.0-7.0, and water to 100 wt%.
  • the pharmaceutical composition of the present invention includes the following components: 0.005wt% of trefarotene, 3wt% of caprylic capric triglyceride, 0.8wt% of sorbitan oleate, 1wt% of phenoxyethanol, 3wt% of ethanol, 0.4wt% of Pemulen TR-1, an appropriate amount of pH adjuster to adjust the pH of the pharmaceutical composition to 5.0-7.0, and water is added to 100wt%.
  • the pharmaceutical composition of the present invention includes the following components: 0.0025wt% of trefarotene, 3wt% of caprylic capric triglyceride, 0.8wt% of sorbitan oleate, 1wt% of phenoxyethanol, 3wt% of ethanol, 0.4wt% of Pemulen TR-1, an appropriate amount of pH adjuster to adjust the pH of the pharmaceutical composition to 5.0-7.0, and water is added to 100wt%.
  • the pharmaceutical composition of the present invention includes the following components: 0.001wt% of trefarotene, 3wt% of caprylic capric triglyceride, 0.8wt% of sorbitan oleate, 1wt% of phenoxyethanol, 3wt% of ethanol, 0.4wt% of Pemulen TR-1, an appropriate amount of pH adjuster to adjust the pH of the pharmaceutical composition to 5.0-7.0, and water is added to 100wt%.
  • the pharmaceutical composition of the present invention includes the following components: 0.0025wt% of trefarotene, 4wt% of caprylic capric triglyceride or caprylic triglyceride, 0.8wt% of sorbitan oleate, 1wt% of phenoxyethanol, 3wt% of ethanol, 0.4wt% of Pemulen TR-1, an appropriate amount of pH adjuster to adjust the pH of the pharmaceutical composition to 5.0-7.0, and water is added to 100wt%.
  • the pharmaceutical composition of the present invention can be prepared according to conventional methods.
  • the present invention also provides a method for preparing the above pharmaceutical composition, comprising the following steps: mixing trefarotene, oil, emulsifier and water.
  • the method comprises the following steps: 1) mixing trefarotene with oil, emulsifier, and optionally solubilizer; 2) mixing other components (such as emulsifying thickener, humectant, antioxidant, lubricant, preservative, etc., if any) with purified water; 3) mixing and shearing the obtained mixture uniformly, adding a pH adjuster (if any) to adjust the pH to 4.5-7.5 (preferably pH 5.0-7.0), and stirring until uniform.
  • a pH adjuster if any
  • the D 50 particle size of the pharmaceutical composition of the present invention is ⁇ 5 ⁇ m, preferably ⁇ 2 ⁇ m , more preferably ⁇ 1.5 ⁇ m, for example ⁇ 1 ⁇ m.
  • the present invention also provides the use of the above-mentioned pharmaceutical composition in the preparation of a drug for preventing and/or treating skin-related diseases.
  • the skin-related diseases include:
  • Acne including acne vulgaris, acne comedonae, acne polymorpha, rosacea, cystic acne, conglobate acne, senile acne, secondary acne such as solar acne, drug-induced acne or occupational acne;
  • Skin keratosis including ichthyosis, ichthyosis-like symptoms, lamellar ichthyosis, Darier's disease, palmoplantar keratosis, leukoplakia, pityriasis rubra pilaris and leukoplakia-like symptoms, skin or mucosal (oral) lichen;
  • cutaneous warts including common warts, flat warts, molluscum contagiosum, and epidermodysplasia verruciformis, or oral or cauliflower papillomatosis;
  • Skin diseases such as immune skin diseases, such as lupus erythematosus, bullous immune diseases and collagen diseases, such as scleroderma;
  • Pigmentation disorders such as hyperpigmentation, melasma, hypopigmentation or vitiligo
  • Symptoms of cancerous or precancerous skin or mucous membranes such as actinic keratosis, Bowen's disease, carcinoma in situ, keratoacanthoma and skin cancers, such as basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and cutaneous lymphomas, such as T-cell lymphoma.
  • BCC basal cell carcinoma
  • SCC squamous cell carcinoma
  • T-cell lymphoma cutaneous lymphomas
  • the skin-related disease is selected from acne, skin keratosis, skin aging (including age aging and photoaging), pigmentation, psoriasis, psoriatic arthritis, dermatitis, eczema, skin warts, skin erythema, stretch marks, athlete's foot, and skin cancer.
  • the pharmaceutical composition of the present invention can be prepared into a variety of preparations, especially topical preparations, such as emulsions, gels, creams, ointments, liniments, etc.
  • the pharmaceutical composition has good stability, small particle size, high uniformity, and low irritation, and effectively improves medication safety and skin comfort.
  • FIG. 1 Microscopic particle structures of different pharmaceutical compositions observed under a microscope of the same magnification, wherein A is the pharmaceutical composition 9 of Example 5, B is the commercially available Aklief cream preparation (Galderma); C is the control composition 2 in Control Example 1;
  • FIG2 is a H&E stained pathological section of the skin irritation test in Test Example 2 of the present invention.
  • FIG3 is a graph showing the therapeutic effects of different trefarotene preparations on photoaging of nude mouse skin in Test Example 3 of the present invention.
  • prevention or treatment means administering the formulation of the present invention to prevent, ameliorate or eliminate a disease or one or more symptoms associated with the disease, and includes: (i) preventing the disease or disease state from occurring in a mammal, especially when such mammal is susceptible to the disease state but has not yet been diagnosed as having the disease state; (ii) inhibiting the disease or disease state, that is, curbing its development; (iii) alleviating the disease or disease state, even if the disease or disease state regresses.
  • terapéuticaally effective amount means an amount of the formulation of the present invention that (i) treats or prevents a specific disease, condition or disorder, (ii) alleviates, ameliorates or eliminates one or more symptoms of a specific disease, condition or disorder, or (iii) prevents or delays the onset of one or more symptoms of a specific disease, condition or disorder described herein.
  • the amount of the formulation of the present invention that constitutes a “therapeutically effective amount” varies depending on the formulation, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by a person skilled in the art based on his or her own knowledge and the present disclosure.
  • the content of the active ingredient trefarotene in the pharmaceutical composition of trefarotene can be in the range of 0.001 to 0.1 wt%, preferably 0.001 to 0.01 wt%, for example 0.001 wt%, 0.002 wt%, 0.0025 wt%, 0.003 wt%, 0.004 wt%, 0.005 wt%, 0.006 wt%, 0.008 wt%, 0.01 wt%, etc.
  • pharmaceutically acceptable excipients refers to substances that have no significant irritation to organisms and will not damage the active ingredients. Suitable excipients may be well known to those skilled in the art.
  • chemical stability refers in particular to the stability of the active ingredient.
  • physical stability refers in particular to the absence of crystallization or precipitation of the active agent, or the absence of phase separation or color change in the composition.
  • composition of the present invention can be prepared into a variety of preparations, especially topical preparations, such as emulsions, gels, creams, ointments, liniments, and the like.
  • the composition of the present invention can be prepared into a drug for treating skin-related diseases, especially for treating acne, skin keratosis, skin aging (including age aging and photoaging), pigmentation, psoriasis, psoriatic arthritis, dermatitis, eczema, skin warts, skin erythema, stretch marks, athlete's foot, skin cancer, etc.
  • the skilled person should also take other parameters into account.
  • the pharmaceutical composition that can be used as a medicament according to the invention must also be formulated according to the pathological state to be treated.
  • the pharmaceutical composition of the present invention may have a non-greasy cosmetic appearance, has lubricating and moisturizing properties, and can improve the comfort of skin medication.
  • the inventors unexpectedly discovered that when sorbitan oleate (Span 80) or oleic acid macrogol glyceride (Labrafil M 1944CS) is used as an emulsifier for a pharmaceutical composition containing trefarotene and oil, a milky white emulsion can be obtained, and the addition of the emulsifier can greatly improve the stability of trefarotene in oil, effectively maintaining the stability of the properties of the pharmaceutical composition.
  • the inventors conducted experiments using equal or different amounts of other ingredients as emulsifiers, but were unable to obtain a composition with a uniform texture.
  • the emulsifier is sorbitan oleate (Span 80) or oleic acid macro
  • the inventors also compared and tested the effects of different oils on the pharmaceutical composition. It was unexpectedly found that the use of oil caprylic capric triglyceride (also known as medium chain triglyceride, medium chain triglyceride) or caprylic triglyceride helps to maintain the stability of the pharmaceutical composition. When other oils, such as monolinoleyl glyceryl, monooleyl glyceryl, etc., are used, the stability of the pharmaceutical composition is poor.
  • caprylic capric triglyceride was purchased from Liaoning Xinxing Pharmaceutical Co., Ltd.
  • caprylic triglyceride was purchased from Jiangsu Southeast Nanomaterials Co., Ltd.
  • Span 80 was purchased from Jiangxi Yipsheng Pharmaceutical Co., Ltd.
  • Span 83 was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
  • Particle size Take about 1g of sample, add 5ml of water, and shake to disperse evenly.
  • the content of trefarotene can be determined by conventional high performance liquid chromatography. Alternatively, the following test conditions can be used:
  • Preparation method According to the components shown in Table 1, trefarotene, oil, solubilizer and emulsifier are mixed to obtain mixture 1; the emulsifying thickener and water are mixed to obtain mixture 2; mixtures 1 and 2 are mixed, stirred for 30 minutes, a pH adjuster is added to adjust the pH to 5-6, and stirred until uniform to obtain the mixture.
  • Preparation method According to the components shown in Table 2, trefarotene, oil, solubilizer, emulsifier, antioxidant and preservative are mixed to obtain mixture 1; emulsifying thickener, moisturizer and water are mixed to obtain mixture 2; mixtures 1 and 2 are mixed, stirred for 30 minutes, sheared for 10 minutes, and pH regulator is added to adjust the pH to 5-6 to obtain the composition.
  • the composition is examined in the same manner as in Example 1.
  • Preparation method According to the components shown in Table 3, trefarotene, oil, solubilizer, emulsifier, lubricant and antioxidant are mixed to obtain mixture 1; emulsifying thickener, moisturizer and water are mixed to obtain mixture 2; mixtures 1 and 2 are mixed, stirred for 30 minutes, sheared for 10 minutes, and pH regulator is added to adjust the pH to 5-6 to obtain the composition.
  • the composition is examined in the same manner as in Example 1.
  • Preparation method According to the components shown in Table 4, trefarotene, oil, solubilizer, emulsifier, lubricant and antioxidant are mixed to obtain mixture 1; emulsifying thickener, moisturizer and water are mixed to obtain mixture 2; mixtures 1 and 2 are mixed, stirred for 30 minutes, and a pH regulator is added to adjust the pH to 5-6 to obtain the composition.
  • the composition is examined in the same manner as in Example 1.
  • Preparation method According to the components shown in Table 5, trefarotene, oil, solubilizer, emulsifier, lubricant and antioxidant are mixed to obtain mixture 1; emulsifying thickener, moisturizer and water are mixed to obtain mixture 2; mixtures 1 and 2 are mixed, stirred for 30 minutes, sheared for 10 minutes, and a pH regulator is added to adjust the pH to 5-6 to obtain the composition.
  • the composition is examined in the same manner as in Example 1.
  • Preparation method According to the components shown in Table 6, trefarotene, oil, solubilizer and emulsifier are mixed to obtain mixture 1; emulsifying thickener, moisturizer and water are mixed to obtain mixture 2; mixtures 1 and 2 are mixed, stirred for 30 minutes, sheared for 10 minutes, and pH regulator is added to adjust the pH to 5-6 to obtain the composition.
  • the composition is examined in the same manner as in Example 1.
  • composition 11 uses Span 80 as an emulsifier and is placed at 60°C for 30 days.
  • the appearance, pH, particle size and content of the composition remain stable, and it has good physical and chemical stability.
  • Composition 12 uses Span 83 as an emulsifier and is placed at 60°C for 30 days.
  • the appearance, pH and particle size of the composition remain stable; but API The content decreased significantly, and the chemical stability was poor.
  • Composition 13 used caprylic triglyceride as the oil and Span 80 as the emulsifier. It was placed at 60°C for 30 days.
  • the appearance, pH, particle size and content remained basically stable, and it had good physical and chemical stability.
  • Composition 14 used mineral oil as the oil and Span 83 as the emulsifier. It was placed at 60°C for 30 days. The appearance, pH and particle size of the composition remained stable; but the API content decreased significantly, and the chemical stability was poor.
  • Preparation method According to the components shown in Table 7, trefarotene, oil, solubilizer and emulsifier are mixed to obtain mixture 1; emulsifying thickener and water are mixed to obtain mixture 2; mixtures 1 and 2 are mixed, stirred for 30 minutes, sheared for 30 minutes, and pH regulator is added to adjust the pH to 5-6 to obtain the composition.
  • the composition is examined in the same manner as in Example 1.
  • the control composition 1 does not contain an emulsifier, and the prepared composition is a white emulsion with a particle size D 50 of 12.8 ⁇ m. Even after shearing, the particle size is still large, D 50 of 3.39 ⁇ m, and the uniformity is poor.
  • the control composition 2 uses polyglycerol oleate (Plurol Oleique CC) as an emulsifier, and the prepared composition is a milky white paste, which is viscous and difficult to apply; and the sample has poor stability. After being placed at 60°C for 30 days, it was observed under a microscope that the emulsion droplets were not round and partially broken (as shown in Figure 1-C).
  • Preparation method According to the components shown in Table 8, trefarotene, oil, solubilizer and emulsifier are mixed to obtain a mixture 1; mix the emulsifying thickener and water to obtain mixture 2; mix mixtures 1 and 2, stir for 30 minutes, shear for 10 minutes, add a pH adjuster to adjust the pH to 5-6, and obtain the composition.
  • the composition is examined in the same manner as in Example 1.
  • Aklief cream is a trefarotene cream preparation approved by the US FDA for topical treatment of acne, and the commercially available Aklief cream is used as a control.
  • Sample A a topical preparation of trefarotene prepared according to the pharmaceutical composition 9 of Example 5;
  • Sample B a commercially available Aklief cream preparation (Galderma, batch number 334212).
  • the microscopic particle structure of the preparation observed at 40 ⁇ 10 magnification using an Olympus CX41RF microscope is shown in FIG1 .
  • FIG. A is a topical preparation of trefarotene prepared from the pharmaceutical composition of the present invention, with a small particle size and good uniformity.
  • FIG. B is a commercially available Aklief cream preparation, with a large particle size and poor uniformity.
  • the purpose of this test example is to investigate the irritation of the trefarotene topical preparation prepared from the pharmaceutical composition of the present invention to the skin by comparing the preparation of the present invention with the commercially available Aklief cream.
  • New Zealand rabbits (2.0-2.5 kg, 16 rabbits, half male and half female, provided by Nanjing Pukou District Life Breeding Farm, production license number: SCXK (Su) 2019-0005) were randomly divided into 4 groups, 4 rabbits in each group, half male and half female. Different test drugs were administered once a day for 7 consecutive days. The different groups were:
  • Group I positive control group, commercially available Aklief cream preparation (Galderma, batch number 334212);
  • Group II trefarotene topical preparation prepared according to pharmaceutical composition 7 of Example 4.
  • Group III trefarotene topical preparation prepared according to pharmaceutical composition 9 of Example 5;
  • Group IV trefarotene topical preparation prepared according to pharmaceutical composition 5 of Example 3.
  • a baby pusher was used to remove hair from the back of the rabbit (no razor or depilatory cream was used, and the skin should not be damaged); the area of each shaved area was approximately 5 ⁇ 5 cm2 .
  • the depilatory area must have clear and neat boundaries and the depilatory area must be consistent.
  • 24 hours after depilation 1 mL of the corresponding preparation was applied to the depilatory area, and the drug was administered once a day for 7 consecutive days. Before each administration, the test drug was washed off with distilled water, and the test drug was applied after the skin of the rabbit's administration area was dried.
  • Skin irritation rating Note: Skin irritation reaction includes erythema and edema, with a maximum total score of 8 points.
  • Table 12 Results of rabbit skin irritation intensity scoring Note: In the above table, “1-24h” refers to the 24th hour observation after administration on the first day; “7-1h” refers to the 1st hour observation after administration on the 7th day; and so on.
  • the score of group I was 1.75, the score of group II was 0.75, and the rabbit skin showed mild irritation; there was no irritation in groups III and IV; on the fifth day, the score of group I was 2, the scores of groups II and III were 1, and the score of group IV was 0.75, and all groups showed mild irritation.
  • group I positive control group
  • group II scored 3 to 4, showing moderate irritation
  • the scores of groups II to IV were ⁇ 2.99, and still only showed mild irritation.
  • the skin irritation of the Aklief cream preparation group is the most obvious, and the trefarotene preparation of group III of the present invention is the least irritating.
  • the H&E staining pathological pictures in Figure 2 show that in group I, obvious hemorrhage and edema can be seen in the dermis, a large number of inflammatory cells infiltrated, a large number of eosinophils (one of the signs of skin allergic reactions) can be seen, the capillaries of the subcutaneous tissue are obviously dilated, and a large number of inflammatory cells infiltrate around the blood vessels; in group II, the inflammatory cell infiltration in the dermis was significantly reduced compared with group I, no obvious eosinophils were seen, there was a small amount of bleeding in the dermis, dilation of blood vessels in the subcutaneous tissue, and inflammatory cell infiltration around the blood vessels; in group III, the inflammatory cell infiltration in the dermis was significantly reduced compared with group I, there were only a few bleeding spots in the dermis, slight dilation of blood vessels in the subcutaneous tissue, and a small amount of inflammatory cell infiltration around the blood vessels; in group
  • the experimental results show that the Aklief cream preparation has obvious skin irritation during use, while the pharmaceutical composition of the present invention significantly reduces the irritation of the preparation to the skin and improves the compliance and comfort of the subjects during use.
  • test example is to compare the preparation of the present invention with the commercially available tretinoin cream.
  • topical preparation of trefarotene prepared by the pharmaceutical composition of the present invention was investigated.
  • Retinoic acid cream is a product approved by the US FDA for the treatment of photoaging.
  • mice 56 healthy nude mice (weight 20-25g, Changzhou Cavens Experimental Animal Co., Ltd.) were randomly divided into 4 groups, half male and half female, and administered according to the dosing regimen in Table 13, where:
  • Blank control group placebo, the difference from the test drug group is that the placebo does not contain trefarotene;
  • Positive control group Retinoic acid cream (concentration 0.02%, Ortho Pharmaceuticals, batch number 356979);
  • the low-dose group of the present invention the concentration of trefarotene is 0.001%, and the prescription is the same as that of the pharmaceutical composition 9 of Example 5, except that the content of trefarotene is different;
  • the high-dose group of the present invention trefarotene concentration 0.005%, i.e., pharmaceutical composition 9 of Example 5;
  • the lamp height is 13cm
  • the UVA irradiation intensity is 0.7546mW/ cm2
  • the UVB irradiation intensity is 0.0269mW/ cm2 , once a day, 5 days a week.
  • Minimum erythema dose MED
  • UVA irradiation dose is 1850mJ/ cm2
  • UVB irradiation dose is 220mJ/ cm2
  • in the first week irradiation is carried out according to 70% of the minimum erythema dose (MED)
  • UVA increases by 650mJ/ cm2 every week
  • UVB increases by 30mJ/ cm2 every week
  • the cumulative dose of UVA is 71.5J/ cm2
  • the cumulative dose of UVB is 6mJ/ cm2 .
  • the nude mice were medicated according to the above experimental scheme.
  • the irradiated area on the back of the nude mice was photographed once a week to observe the treatment effect (as shown in Figure 3), and then the skin on the back of the nude mice was scored according to the scoring criteria, and the evaluation criteria are shown in Table 14.
  • the scoring results are shown in Table 15.
  • the score of the blank control group was 4.36, that of the low-dose trefarotene group of the present invention was 1.36, and that of the high-dose trefarotene group was 1.14, indicating that the test drug trefarotene has a good therapeutic effect on skin photoaging.
  • the concentration of trefarotene in the test drugs of the present invention at different doses is much lower than that of the positive control drug retinoic acid (0.02%)
  • the skin wrinkle scores of the trefarotene at different doses are better than those of the positive control group and much better than those of the blank group, showing a superior anti-wrinkle efficacy.
  • the pharmaceutical composition of the present invention can be prepared into a trefarotene topical preparation with uniform texture and small particle size, and various components including oils and emulsifiers have good compatibility with the active ingredient trefarotene, so that the composition can maintain good physical and chemical stability, and has very low irritation, good medication safety and skin comfort.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant du trifarotène, comprenant du trifarotène, une graisse, un émulsifiant et de l'eau, la graisse étant choisie parmi au moins l'un parmi le triglycéride caprique caprylique, le triglycéride caprylique, le myristate d'isopropyle et l'huile minérale ; l'émulsifiant est choisi parmi au moins l'un parmi l'oléate de sorbitane et le glycéride de polyéthylène glycol d'acide oléique. L'ajout de l'émulsifiant amène la composition à avoir une texture uniforme et améliore considérablement la stabilité du trifarotène dans la graisse, stabilisant ainsi efficacement les propriétés physiques et chimiques de la composition pharmaceutique, réduisant l'irritation, et améliorant efficacement la sécurité d'utilisation de médicament et le confort de la peau.
PCT/CN2023/135836 2022-12-02 2023-12-01 Composition pharmaceutique comprenant du trifarotène et son utilisation WO2024114789A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211543234 2022-12-02
CN202211543234.1 2022-12-02

Publications (1)

Publication Number Publication Date
WO2024114789A1 true WO2024114789A1 (fr) 2024-06-06

Family

ID=91236652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/135836 WO2024114789A1 (fr) 2022-12-02 2023-12-01 Composition pharmaceutique comprenant du trifarotène et son utilisation

Country Status (2)

Country Link
CN (1) CN118121532A (fr)
WO (1) WO2024114789A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1943567A (zh) * 2006-10-12 2007-04-11 华东理工大学 维a酸类药物的自微乳化组合物及其制备方法
CN104507469A (zh) * 2012-06-01 2015-04-08 盖尔德马研究及发展公司 含有类维生素a的水包油乳液型局部组合物
CN104507470A (zh) * 2012-06-01 2015-04-08 盖尔德马研究及发展公司 含有类维生素a的o/w乳液类型的局部药物组合物
CN110062618A (zh) * 2016-12-13 2019-07-26 宝洁公司 包含类视色素的稳定个人护理组合物
US20210220269A1 (en) * 2018-09-28 2021-07-22 Galderma Research & Development Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses
CN113559083A (zh) * 2013-12-04 2021-10-29 盖尔德马研究及发展公司 包含类维生素a的脂质微胶囊

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1943567A (zh) * 2006-10-12 2007-04-11 华东理工大学 维a酸类药物的自微乳化组合物及其制备方法
CN104507469A (zh) * 2012-06-01 2015-04-08 盖尔德马研究及发展公司 含有类维生素a的水包油乳液型局部组合物
CN104507470A (zh) * 2012-06-01 2015-04-08 盖尔德马研究及发展公司 含有类维生素a的o/w乳液类型的局部药物组合物
CN113559083A (zh) * 2013-12-04 2021-10-29 盖尔德马研究及发展公司 包含类维生素a的脂质微胶囊
CN110062618A (zh) * 2016-12-13 2019-07-26 宝洁公司 包含类视色素的稳定个人护理组合物
US20210220269A1 (en) * 2018-09-28 2021-07-22 Galderma Research & Development Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses

Also Published As

Publication number Publication date
CN118121532A (zh) 2024-06-04

Similar Documents

Publication Publication Date Title
US7939516B2 (en) Topical skin care composition
EP2419082B1 (fr) Composition pharmaceutique topique comprenant un principe actif sensible a l'eau
EP1915133A1 (fr) Émulsion de type huile-dans-eau pour application topique en dermatologie
WO2004064769A2 (fr) Methodes de production et d'utilisation d'agents d'administration topique
US10028972B2 (en) Pharmaceutical compositions of anti-acne agents
US9622950B2 (en) Compositions for use in treatment of dermatological diseases and conditions
CN107158086B (zh) 具有缓解瘙痒功效的皮肤养护/治疗组合物
WO2020186212A1 (fr) Nouvelle nano-formulation de cannabidiol (cbd) et d'autres cannabinoïdes pour le traitement de maladies de la peau
US9855244B2 (en) O/W-emulsion-type topical pharmaceutical compositions containing a retinoid
Ghosh et al. Recent advancements in nanocarrier based therapy against acne: The role of biosurfactants and status of patents
EP2872116B1 (fr) Composition dermatologique comprenant des oléosomes et des rétinoïdes, son procédé de préparation et son utilisation
WO2024114789A1 (fr) Composition pharmaceutique comprenant du trifarotène et son utilisation
CA2929292C (fr) Composition pharmaceutique topique d'acitretine
WO2012053014A2 (fr) Procédé de traitement de l'acné à l'aide de compositions pharmaceutiques de clindamycine et d'adapalène
WO2012053010A2 (fr) Procédé de traitement de l'acné à l'aide de compositions pharmaceutiques de clindamycine
WO2024125500A1 (fr) Composition pharmaceutique topique et son utilisation en médecine
EP4306112A1 (fr) Nouveau regime posologique d'une composition comprenant de la brimonidine pour son utilisation dans la prevention et le traitement des dommages cutanes resultant d'un rayonnement
Pielenhofer Quality, safety and efficacy of a novel nanoparticulate imiquimod formulation
WO2022140467A1 (fr) Compositions topiques et procédés de traitement de maladies et d'états cutanés avec de telles compositions
US9084778B2 (en) Topical compositions containing a retinoid of the oil-in-water emulsion type
WO2023247796A1 (fr) Composition de soins de la peau
KR20050085740A (ko) 염기를 이용하여 용매 내에서 가용화된 레티노이드를화학적으로 안정화시키는 방법
CN117618577A (zh) 一种改善皮肤疾病症状的组合物半固体制剂